Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$14.64
-7.0%
$14.59
$3.44
$20.21
$159.21M0.4386,163 shs53,469 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.15
-2.6%
$24.52
$14.59
$44.28
$565.05M1.11438,261 shs664,487 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$15.96
+1.0%
$15.54
$13.46
$31.04
$470.01M0.88563,843 shs435,845 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
+6.8%
$29.36
$4.30
$31.70
$497.21MN/AN/A4.25 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-7.05%-2.40%+9.58%+35.06%+103.84%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-2.58%-26.67%-22.86%-43.10%+6.58%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+1.01%+6.97%+4.31%-30.52%-21.34%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$14.64
-7.0%
$14.59
$3.44
$20.21
$159.21M0.4386,163 shs53,469 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.15
-2.6%
$24.52
$14.59
$44.28
$565.05M1.11438,261 shs664,487 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$15.96
+1.0%
$15.54
$13.46
$31.04
$470.01M0.88563,843 shs435,845 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
+6.8%
$29.36
$4.30
$31.70
$497.21MN/AN/A4.25 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-7.05%-2.40%+9.58%+35.06%+103.84%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-2.58%-26.67%-22.86%-43.10%+6.58%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
+1.01%+6.97%+4.31%-30.52%-21.34%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.50
Moderate Buy$31.00111.75% Upside
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.90
Moderate Buy$44.57145.57% Upside
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.20
Hold$27.0069.17% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BDSX, CSTL, MCTA, and FLGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetBuy$50.00 ➝ $40.00
5/7/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
DowngradeSell (D)Sell (D-)
5/7/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetOutperform$44.00 ➝ $43.00
5/5/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Reiterated RatingNeutral$30.00 ➝ $15.00
5/5/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Boost Price TargetBuy$20.00 ➝ $22.00
5/4/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Reiterated RatingSell (D-)
4/27/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
UpgradeHoldStrong-Buy
4/20/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lower Price TargetBuy$50.00 ➝ $40.00
3/2/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
UpgradeBuy
3/2/2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
DowngradeStrong-BuyHold
2/27/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
UpgradeMarket PerformOutperform
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$88.50M1.67N/AN/A$0.90 per share16.27
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$344.23M1.60$1.08 per share16.74$15.21 per share1.19
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.47N/AN/A$35.10 per share0.45
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%N/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BDSX, CSTL, MCTA, and FLGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million
5/4/2026Q1 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million
2/27/2026Q4 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million
2/26/2026Q4 2025
Biodesix, Inc. stock logo
BDSX
Biodesix
-$1.05-$0.49+$0.56-$0.49$26.25 million$28.76 million
2/26/2026Q4 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.23-$0.08+$0.15-$0.08$81.19 million$81.88 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
5.09
2.82
2.82
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
6.75
6.53
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
5.31
5.31
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
23.20%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.10%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
22010.11 million7.76 millionNo Data
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54030.33 million28.48 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31529.75 million18.99 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A

Recent News About These Companies

Chinese Stocks To Watch Today - May 12th
Best Chinese Stocks To Follow Today - May 9th
Chinese Stocks To Follow Today - May 7th
Chinese Stocks To Watch Today - May 5th
Best Chinese Stocks To Research - May 4th
Promising Chinese Stocks To Research - May 3rd
Chinese Stocks To Consider - May 2nd
Best Chinese Stocks To Consider - May 1st
Best Chinese Stocks To Follow Now - April 29th
Promising Chinese Stocks To Watch Today - April 27th
Top Chinese Stocks To Watch Now - April 26th
Promising Chinese Stocks To Research - April 25th
Chinese Stocks Worth Watching - April 24th
Top Chinese Stocks Worth Watching - April 23rd
Best Chinese Stocks To Follow Today - April 22nd
Top Chinese Stocks To Consider - April 21st
Chinese Stocks To Follow Now - April 20th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$14.64 -1.11 (-7.05%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$14.55 -0.09 (-0.61%)
As of 05/13/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$18.15 -0.48 (-2.58%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$18.18 +0.03 (+0.14%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$15.96 +0.16 (+1.01%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$15.96 0.00 (0.00%)
As of 05/13/2026 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 +1.86 (+6.76%)
As of 05/13/2026 03:30 PM Eastern

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.